Registro Tumori del Veneto, Regione del Veneto, Padova, Italy.
Gastroenterology Unit, Nuovo Regina Margherita Hospital, Rome, Italy.
Gut. 2018 Dec;67(12):2124-2130. doi: 10.1136/gutjnl-2017-314753. Epub 2017 Nov 3.
The long-term performance of colorectal cancer (CRC) screening programmes based on a 2-year faecal immunochemical test (FIT) is still unclear.
In a sample of 50 to 69-year-olds repeatedly screened with the FIT (OC-Hemodia latex agglutination test; cut-off: 20 µg haemoglobin/g faeces), we examined: (1) the FIT positivity rate, the CRC and advanced adenoma detection rate and the FIT's positive predictive value (PPV) for advanced neoplasia, at each round of screening and (2) the cumulative CRC and advanced adenoma detection rate after five rounds of FIT.
Over 12 years (2002-2014), 123 347 individuals were administered the FIT up to six times, and 781 CRCs and 4713 advanced adenomas were diagnosed. The CRC and advanced adenoma detection rates declined substantially from the first to the third (rate ratio (RR) 0.25, 95% CI 0.20 to 0.32) and second (RR 0.51, 95% CI 0.47 to 0.56) rounds, respectively, and then remained stable. The PPV for advanced neoplasia dropped by 18% in the second round (RR 0.82, 95% CI 0.77 to 0.89), with no further reduction thereafter due to a concomitant decline in the FIT positivity rate (RR first to sixth rounds: 0.56, 95% CI 0.53 to 0.60).The cumulative CRC and advanced adenoma detection rates over five consecutive rounds were 8.5‰ (95% CI 7.8 to 9.2), and 58.9‰ (95% CI 56.9 to 61.0), respectively.
Repeated FIT significantly reduces the burden of colorectal disease while facilitating an efficient use of colonoscopy resources. The cumulative detection rate after five rounds of FIT is similar to primary screening with colonoscopy, supporting the need to account for the cumulative sensitivity of repeated FITs when evaluating the test's efficacy.
基于每两年进行一次粪便免疫化学检测(FIT)的结直肠癌(CRC)筛查项目的长期效果仍不明确。
在一个通过 FIT(OC-Hemodia 乳胶凝集试验;截断值:20μg 血红蛋白/g 粪便)反复筛查的 50 岁至 69 岁人群样本中,我们检测了:(1)在每轮筛查时的 FIT 阳性率、CRC 和高级腺瘤检出率以及 FIT 对高级肿瘤的阳性预测值(PPV),以及(2)在进行了五轮 FIT 后,CRC 和高级腺瘤的累积检出率。
在 12 年(2002 年至 2014 年)期间,共有 123347 人接受了最多六次的 FIT 检测,并诊断出 781 例 CRC 和 4713 例高级腺瘤。CRC 和高级腺瘤的检出率从第一轮(率比(RR)0.25,95%CI 0.20 至 0.32)和第二轮(RR 0.51,95%CI 0.47 至 0.56)筛查开始显著下降,之后一直保持稳定。第二轮的高级肿瘤 PPV 下降了 18%(RR 0.82,95%CI 0.77 至 0.89),此后由于 FIT 阳性率的下降(RR 第一至第六轮:0.56,95%CI 0.53 至 0.60),PPV 没有进一步下降。连续五轮的 CRC 和高级腺瘤累积检出率分别为 8.5‰(95%CI 7.8 至 9.2)和 58.9‰(95%CI 56.9 至 61.0)。
重复的 FIT 显著降低了结直肠疾病的负担,同时促进了结肠镜检查资源的有效利用。五轮 FIT 后的累积检出率与结肠镜初筛相似,这支持在评估该检测的效果时,需要考虑重复 FIT 的累积敏感性。